慢性冠脉综合征长期口服抗凝患者加用阿司匹林的研究
这项在法国开展的多中心、双盲、随机、安慰剂对照试验纳入既往支架植入超过6个月、高动脉血栓风险且长期口服抗凝的慢性冠脉综合征患者,1:1随机接受阿司匹林100 mg每日一次或安慰剂,所有患者继续原口服抗凝治疗。共随机872例(阿司匹林组433例、安慰剂组439例),中位随访2.2年时因阿司匹林组全因死亡过多,经独立数据与安全监察委员会建议提前终止。阿司匹林组主要疗效终点事件73例(16.9%) vs 安慰剂组53例(12.1%),校正HR 1.53(95%CI 1.07–2.18,P=0.02);全因死亡58例(13.4%) vs 37例(8.4%),校正HR 1.72(95%CI 1.14–2.58,P=0.01);大出血44例(10.2%) vs 15例(3.4%),校正HR 3.35(95%CI 1.87–6.00,P<0.001)。
要点
- 高动脉血栓风险且长期口服抗凝的慢性冠脉综合征患者,加用阿司匹林100 mg每日一次组主要疗效终点事件16.9% vs 安慰剂组12.1%,校正HR 1.53(95%CI 1.07–2.18,P=0.02)。
- 阿司匹林组全因死亡13.4% vs 安慰剂组8.4%,校正HR 1.72(95%CI 1.14–2.58,P=0.01),试验因阿司匹林组死亡过多提前终止。
- 阿司匹林组大出血10.2% vs 安慰剂组3.4%,校正HR 3.35(95%CI 1.87–6.00,P<0.001)。
- 严重不良事件阿司匹林组467例次 vs 安慰剂组395例次。
- 入组条件为既往支架植入超过6个月、高动脉血栓风险、正在长期口服抗凝的慢性冠脉综合征患者。
适用人群与场景
- 法国多中心纳入的慢性冠脉综合征患者,既往支架植入超过6个月(入组前),高动脉血栓风险,且正在接受长期口服抗凝治疗。
- 所有患者继续原口服抗凝治疗,随机加用阿司匹林100 mg每日一次或安慰剂。
处置流程与药物剂量
- 阿司匹林组:阿司匹林100 mg每日一次口服,联合继续原口服抗凝治疗。
- 对照组:安慰剂,联合继续原口服抗凝治疗。
研究设计与关键结果
- 多中心、双盲、随机、安慰剂对照试验,共随机872例:阿司匹林组433例、安慰剂组439例,中位随访2.2年。
- 主要疗效终点(心血管死亡、心肌梗死、卒中、系统性栓塞、冠脉血运重建或急性肢体缺血的复合终点):阿司匹林组73例(16.9%) vs 安慰剂组53例(12.1%),校正HR 1.53(95%CI 1.07–2.18,P=0.02)。
- 全因死亡:阿司匹林组58例(13.4%) vs 安慰剂组37例(8.4%),校正HR 1.72(95%CI 1.14–2.58,P=0.01);试验因阿司匹林组全因死亡过多,经独立数据与安全监察委员会建议提前终止。
- 大出血:阿司匹林组44例(10.2%) vs 安慰剂组15例(3.4%),校正HR 3.35(95%CI 1.87–6.00,P<0.001)。
- 严重不良事件:阿司匹林组467例次 vs 安慰剂组395例次。
证据类型、等级与局限
- 证据类型:多中心、双盲、随机、安慰剂对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于高动脉血栓风险、正在长期口服抗凝的慢性冠脉综合征患者,本研究显示加用阿司匹林100 mg每日一次较安慰剂增加主要疗效终点事件、全因死亡和大出血风险,试验因此提前终止。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The appropriate antithrombotic regimen for patients with chronic coronary syndrome who are at high atherothrombotic risk and receiving long-term oral anticoagulation remains unknown.
METHODS: We conducted a multicenter, double-blind, randomized, placebo-controlled trial in France involving patients with chronic coronary syndrome who had undergone a previous stent implantation (>6 months before enrollment) and were at high atherothrombotic risk and currently receiving long-term oral anticoagulation. The patients were randomly assigned in a 1:1 ratio to receive aspirin (100 mg once daily) or placebo; all the patients continued to receive their current oral anticoagulation therapy. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, stroke, systemic embolism, coronary revascularization, or acute limb ischemia. The key safety outcome was major bleeding.
RESULTS: A total of 872 patients underwent randomization; 433 were assigned to the aspirin group, and 439 to the placebo group. The trial was stopped early at the advice of the independent data and safety monitoring board after a median follow-up of 2.2 years because of an excess of deaths from any cause in the aspirin group. A primary efficacy outcome event occurred in 73 patients (16.9%) in the aspirin group and in 53 patients (12.1%) in the placebo group (adjusted hazard ratio, 1.53; 95% confidence interval [CI], 1.07 to 2.18; P = 0.02). Death from any cause occurred in 58 patients (13.4%) in the aspirin group and in 37 (8.4%) in the placebo group (adjusted hazard ratio, 1.72; 95% CI, 1.14 to 2.58; P = 0.01). Major bleeding occurred in 44 patients (10.2%) in the aspirin group and in 15 patients (3.4%) in the placebo group (adjusted hazard ratio, 3.35; 95% CI, 1.87 to 6.00; P<0.001). A total of 467 and 395 serious adverse events were reported in the aspirin group and placebo group, respectively.
CONCLUSIONS: Among patients with chronic coronary syndrome at high atherothrombotic risk who were receiving an oral anticoagulant, the addition of aspirin led to a higher risk of cardiovascular death, myocardial infarction, stroke, systemic embolism, coronary revascularization, or acute limb ischemia than placebo, as well as higher risks of death from any cause and major bleeding. (Funded by the French Ministry of Health and Bayer Healthcare; ClinicalTrials.gov number, NCT04217447.).
参考来源
- Lemesle G, Didier R, Steg PG, et al. Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation. N Engl J Med. 2025. PMID: 40888725. doi:10.1056/NEJMoa2507532
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。